GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » EV-to-Revenue

Aytu BioPharma (STU:AY20) EV-to-Revenue : 0.09 (As of Jun. 01, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Aytu BioPharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aytu BioPharma's enterprise value is €6.47 Mil. Aytu BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was €75.75 Mil. Therefore, Aytu BioPharma's EV-to-Revenue for today is 0.09.

The historical rank and industry rank for Aytu BioPharma's EV-to-Revenue or its related term are showing as below:

STU:AY20' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.48   Med: 0.15   Max: 4.66
Current: 0.18

During the past 13 years, the highest EV-to-Revenue of Aytu BioPharma was 4.66. The lowest was -2.48. And the median was 0.15.

STU:AY20's EV-to-Revenue is ranked better than
96.71% of 973 companies
in the Drug Manufacturers industry
Industry Median: 2.43 vs STU:AY20: 0.18

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-01), Aytu BioPharma's stock price is €1.76. Aytu BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €12.82. Therefore, Aytu BioPharma's PS Ratio for today is 0.14.


Aytu BioPharma EV-to-Revenue Historical Data

The historical data trend for Aytu BioPharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma EV-to-Revenue Chart

Aytu BioPharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.80 1.72 0.26 0.02 0.16

Aytu BioPharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.16 0.14 0.08 0.13

Competitive Comparison of Aytu BioPharma's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aytu BioPharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's EV-to-Revenue falls into.


;
;

Aytu BioPharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aytu BioPharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=6.465/75.745
=0.09

Aytu BioPharma's current Enterprise Value is €6.47 Mil.
Aytu BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €75.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aytu BioPharma  (STU:AY20) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aytu BioPharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.76/12.823
=0.14

Aytu BioPharma's share price for today is €1.76.
Aytu BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aytu BioPharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aytu BioPharma Business Description

Traded in Other Exchanges
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines